Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen and Quest to Develop Arterial Disease Dx

NEW YORK (GenomeWeb News) — Ciphergen and Quest Diagnostics plan to jointly develop a blood-based test for the detection of peripheral artery disease.
 
The deal is the second of a three-part alliance the firms formed last year in which Quest will use Ciphergen’s SELDI-based ProteinChip technology to create the test. The first incarnation resulted in a test that triages ovarian cancer.
 
As part of that deal, Quest bought a 17-percent stake in Ciphergen and agreed to a five-year warrant to by another 2.2 million shares at $3.50 a share, for an aggregate of $15 million.
 
Under that alliance, Quest also agreed to loan Ciphergen as much as $10 million for research expenses, which would be forgiven based on milestone achievements.  
 
Today, Ciphergen President and CEO Gail Page said the ovarian tumor test is “making excellent progress.”
 
Ciphergen said it is developing the PAD blood test with Stanford University. The company said that 75 percent of the people who suffer from PAD, which is caused by arterial plaque, do not experience symptoms, which could make an early warning test valuable.  
 
Financial terms of this agreement were not released.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.